Eric Racine is vice president, president and head, North America Public Affairs for Sanofi. He is responsible for Sanofi’s worldwide patient advocacy strategy to enhance the company’s commitment to patient centricity and strengthen how Sanofi partners with patient advocates. Eric joined Sanofi in 2002 and has held progressive leadership positions spanning medical marketing, market access, healthcare policy and corporate affairs.
Before he joined the pharmaceutical industry, Eric held various academic, clinical and management positions. He has a doctor of pharmacy degree from Wayne State University in Michigan and an executive MBA from Rutgers University.
Jeffrey Rein is the retired chairman and chief executive officer for Walgreens, the nation’s largest drugstore chain. He joined the company as an assistant store manager in 1982. After several increasingly responsible positions, in 2006 he became CEO. He's a UA graduate, earning his accounting degree in 1974 and his pharmacy degree in 1980, He serves on the board of directors for the Meijer Company, Midtown Educational Foundation, Midwest Young Artists and University of Arizona Eller College National Advisory Board.
Mary J. Ryan is an emeritus board member who worked for Medco Health Solutions, Inc., from 1988 until 2012. She is retired as vice president, corporate regulatory group, responsible for interface with various regulatory agencies, including state boards of pharmacy and departments of insurance. Mary graduated from UA with a bachelor of science in pharmacy in 1974. She completed her master’s degree in business administration at Arizona State University in 1983. She is a member of the American Pharmacists Association and the chair of the Legislative and Regulatory Action Committee at the Academy of Managed Care Pharmacy.
Rick G. Shnellmann, PhD, is dean of the University of Arizona College of Pharmacy. A leading pharmacologist, researcher and drug discovery entrepreneur, he joined the UA in August 2016. Dr. Schnellmann earned his doctorate in pharmacology and toxicology from the University of Arizona College of Pharmacy and Medicine in 1984. Previously, Dr. Schnellmann worked at the South Carolina College of Pharmacy at the Medical University of South Carolina (MUSC) in Charleston, where he was eminentscholar and distinguished university professor and was chair of the college's Department of Drug Discovery and Biomedical Sciences from 2001 to 2015. Under his guidance, his department's NIH grant funding increased, and in 2014 the school was ranked 11th in NIH funding among colleges of pharmacy. Dr. Schnellmann's research is focused on identifying and developing drugs to treat acute kidney injury, diabetic kidney disease, stroke, spinal cord injury and Parkinson's disease. His research has been funded continuously since 1987 and includes NIH grant funding totaling more than $30 million. He has been instrumental in founding three MUSC spin-off biotechnology companies focused on drug discovery and development.
Bruce Seligmann is the co-founder and CSO of BioSpyder Technologies, Inc., and is conducting research in collaboration with the University of Arizona Cancer Center. He's also the co-founder, director, chief science officer and vice president of research at High Throughput Genomics based in Tucson. Through his work, Bruce has provided time-and cost-saving technology that assists the advancement of research, drug discovery and the development of better therapies and diagnostics. Bruce is also the founder of Systems Integration Drug Discovery Co., which was sold to Discovery Partners International. Before that, he was the vice president of research and development and the center director at the biotech company Selectide.